Douglas Tremblay, MD

Articles by Douglas Tremblay, MD

Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies

ByKelsey Sokol, MD,Douglas Tremblay, MD,Sheena Bhalla, MD,Raajit Rampal, MD, PhD,John O. Mascarenhas, MD

May 15th 2018

In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia

ByDouglas Tremblay, MD,Kelsey Sokol, MD,Sheena Bhalla, MD,Raajit Rampal, MD, PhD,John O. Mascarenhas, MD

April 15th 2018

In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.

Latest Updated Articles

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
Published: April 15th 2018 | Updated:
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
Published: May 15th 2018 | Updated:

Douglas Tremblay, MD

Articles by Douglas Tremblay, MD

Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma